The global sepsis diagnostics market is projected to generate $1,109.0 million revenue by 2030, advancing at a CAGR of 9.2% during 2022–2030. This will be on account of the increase in the initiatives taken by government bodies to support R&D for sepsis diagnosis, rise in the infectious disease incidence, and spur in the number of surgical procedures.
In recent years, a drastic increase in the incidence of neurological disorders, traumatic injuries, and cardiovascular diseases and the introduction of advanced surgical technologies has been witnessed. Due to the increase in the number of these surgeries, the risk of HAI infections is increasing, thereby intensifying the demand for sepsis diagnosis. For instance, every year, the number of people suffering from neurological illnesses or accidents is about 20 million, around 14 million of whom require surgery. Additionally, the lack of compliance with sterilization and other hygienic practices in medical facilities is increasing the risk of HAIs, thereby sepsis.
Furthermore, there are many awareness programs introduced by various government and non-profit organizations to reduce the loss of lives globally, which is expected to provide ample opportunities to the market. For instance, according to the CDC, 6–7% of the population loses its life due to HAIs in developed countries, whereas in developing countries, about 10–12% of the population is affected by these infections.
The microbiology category accounted for the largest revenue share, around 50%, and it is expected to grow at a CAGR of more than 8% during 2022–2030. This is attributed to the low cost of microbiology techniques and their widespread use for the diagnosis of sepsis.
The APAC market is expected to witness the highest CAGR, more than 10%, in the forecast period, on account of the technological advancements in the field of diagnostics in the region and promulgating government funding for R&D activities for advanced diagnostics. In the APAC region, China accounts for the largest market share, due to the surge in the incidence of HAIs and rising in the number of product approvals. Furthermore, the development of newer methods for the rapid detection of sepsis is expected to have a positive impact on market growth.
North America accounted for around a 40% market share in 2022, due to the high rate of sepsis in the region, high prevalence and mortality rate associated with infections, and mounting product innovation. To seek new cost-effective methods of sepsis diagnosis in the Canada, the Ministry of Health announced an investment of around $5.7 million to support sepsis research in July 2020 by a new national research network, which will improve the treatment and recovery of sepsis patients. Thus, the rising research and development expenditure in the concerned field will contribute significantly to the market growth.
The major players operating in the global sepsis diagnostics market are bioMérieux SA, Becton, Dickinson and Company, Danaher Corporation, T2 Biosystems Inc., Luminex Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bruker Corporation, Abbott Laboratories, and Immunexpress Inc.